S&P 500 FUTURES SLIDE WITH FED'S POWELL IN SPOTLIGHT

U.S. central bank widely expected to keep rates at 23-year high later Wednesday

Medexus Pharmaceuticals Inc. (MEDXF)

Other OTC - Other OTC Delayed Price. Currency in USD

Add to watchlist

1.3450

-0.1050

(-7.24%)

At close: 02:34PM EDT

Loading interactive chart...

Newsfile
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.Event: 2024 Bloom Burton & Co. Healthcare Investor ConferenceDate: April 16-17, 2024Location: Toronto, OntarioMedexus Presentation: Wednesday, April 17 at 1:30 PM Eastern timeKen d'Entremont, Medexus's Chief Executive
Newsfile
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application (sBLA) for IXINITY® [coagulation factor IX (recombinant)] for the on-dem
Simply Wall St.
Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Slashed Next Year's Estimates
The analysts covering Medexus Pharmaceuticals Inc. ( TSE:MDP ) delivered a dose of negativity to shareholders today, by...